Table 2 DMTs in the treatment of MS
DMTs recommended for pwMS with moderate disease activity, 1st choice in escalation | dose and route of administration |
|---|---|
interferon-beta-1b (Betaferon) interferon-beta-1a (Avonex) interferon-beta-1a (Rebif) PEG-interferon-beta-1a (Plegridy) | 8 MIU s.c. every other day 30 ug i.m./week 44 ug s.c. 3 times/week 125 ug s.c. / 2 weeks |
glatiramer acetate (Copaxone) | 40 mg s.c. 3 times/week |
teriflunomide (Aubagio) | 14 mg/day |
dimethyl fumarate (Tecfidera) | 1st week 2 × 120 mg from the 2nd week 2 × 240 mg |
diroximel fumarate (Vumerity) | 1st week 2 × 231 mg from the 2nd week 2 × 462 mg |
DMTs recommended for pwMS with high disease activity for escalation or as 1st choice* | dose and route of administration |
fingolimod (Gilenya) | 0.5 mg/day |
siponimod (Mayzent) | Depending on the CYP2C9 genotype: Genotypes *1/*1, *1/2 or *2/*2 Days 1–2: 0.25 mg Day 3: 0.5 mg Day 4: 0.75 mg, then 1 mg/day |
ozanomid (Zeposia) | Day 1–4: 0.23 mg Day 5–7: 0.46 mg, then 0.92 mg/day |
ponezimod (Ponvory) | Days 1–2: 2 mg Days 3–4: 3 mg Days 5–6: 4 mg Day 7: 5 mg Day 8: 6 mg Day 9: 7 mg. Day 10: 8 mg Day 11: 9 mg, Day 12-14: 10mg, then 20mg/day |
cladribine (Mavenclad) | 3.5 mg/kg divided into 2 yearly courses 1 course = 2 cycles of 4-5days 23–27 days apart |
natalizumab (Tysabri) | 300 mg i.v./month or also available in 2 × 150 mg s.c./ month |
alemtuzumab (Lemtrada) | 2 cycles 12 months apart 1st cycle: 12 mg i.v. for 5 days 2nd cycle: 12 mg i.v. for 3 days |
ocrelizumab (Ocrevus) | Day 1 and 15: 300 mg i.v., than every 6 months 600 mg i.v. |
ofatumumab (Kesimpta) | 20 mg s.c. Induction: Day 1, 7 and 14: 20 mg s.c., than every 4 weeks 20 mg s.c. |